• -Pneumonie;cIAI =
• +Pneumonie; cIAI =
• -Infektionen;cSSTI =
• -Complicated skin
• +Infektionen; cSSTI
• += Complicated skin
• -en;HAP = hospital-ac
• -quired pneumonia =
• +en; HAP = hospital-a
• +cquired pneumonia =
• -e;VAP = ventilator-a
• -ssociated pneumonia
• -= beatmungsassoziier
• -te Pneumonie;RP =
• +e; VAP = ventilator-
• +associated pneumonia
• + = beatmungsassoziie
• +rte Pneumonie; RP =
• -;DFI = diabetic
• +; DFI = diabetic
• -ktionen.* Prozentual
• -e Differenz der
• +ktionen. * Prozentua
• +le Differenz der
• -berechnet.** Adjusti
• -erte (gemäss "Random
• - effects" -Modell
• -mit Studiengewichtun
• -g) Gesamt-Risikodiff
• -erenzschätzung und
• -95%-Konfidenzinterva
• -ll.a VAP und Non-VAP
• - sind Untergruppen
• -der HAP.Anmerkung:
• +berechnet. **
• +Adjustierte (gemäss
• +"Random effects"
• +-Modell mit Studieng
• +ewichtung) Gesamt-Ri
• +sikodifferenzschätzu
• +ng und 95%-Konfidenz
• +intervall. a VAP
• +und Non-VAP sind
• +Untergruppen der
• +HAP. Anmerkung:
• -Enterococcus spp. † (einschliesslich vancomycin-resistente Isolate)Listeria
• -monocytogenesStaphylococcus aureus* (einschliesslich methicillin-resistente Isolate)Staphylococcus
• -epidermidis (einschliesslich methicillin-resistente Isolate)Staphylococcus
• -haemolyticusStreptococcus agalactiae*Streptococcus pyogenes*Streptococcus pneumoniae †Streptococci
• -der Viridans-Gruppe †
• +Enterococcus spp. † (einschliesslich vancomycin-resistente Isolate) Listeria monocytogenes
• +Staphylococcus aureus* (einschliesslich methicillin-resistente Isolate) Staphylococcus epidermidis
• +(einschliesslich methicillin-resistente Isolate) Staphylococcus haemolyticus Streptococcus
• +agalactiae* Streptococcus pyogenes* Streptococcus pneumoniae † Streptococci der Viridans-Gruppe †
• -Aeromonas hydrophilaCitrobacter freundii*Citrobacter koseriEscherichia coli*Haemophilus
• -influenzae*Legionella pneumophila*Moraxella catarrhalis*Neisseria gonorrhoeaeNeisseria
• -meningitidisPasteurella multocida
• +Aeromonas hydrophila Citrobacter freundii* Citrobacter koseri Escherichia coli* Haemophilus
• +influenzae* Legionella pneumophila* Moraxella catarrhalis* Neisseria gonorrhoeae Neisseria
• +meningitidis Pasteurella multocida
• -Clostridioides difficileClostridium perfringens *Peptostreptococcus spp. †Porphyromonas
• -spp.Prevotella spp.
• +Clostridioides difficile Clostridium perfringens * Peptostreptococcus spp. † Porphyromonas spp.
• +Prevotella spp.
• -Chlamydia pneumoniaeMycobacterium abscessusMycobacterium chelonaeMycobacterium fortuitumMycoplasma
• -pneumoniae
• +Chlamydia pneumoniae Mycobacterium abscessus Mycobacterium chelonae Mycobacterium fortuitum
• +Mycoplasma pneumoniae
• -Acinetobacter baumaniiEnterobacter cloacae*Klebsiella aerogenesKlebsiella oxytoca*Klebsiella
• -pneumoniae*Morganella morganiiSalmonella spp.Serratia marcescensShigella spp.Stenotrophomonas
• +Acinetobacter baumanii Enterobacter cloacae* Klebsiella aerogenes Klebsiella oxytoca* Klebsiella
• +pneumoniae* Morganella morganii Salmonella spp. Serratia marcescens Shigella spp. Stenotrophomonas
• -Bacteroides fragilis Gruppe †Parabacteroides distasonis
• +Bacteroides fragilis Gruppe † Parabacteroides distasonis
• -Providencia spp.Proteus spp.Pseudomonas aeruginosa
• +Providencia spp. Proteus spp. Pseudomonas aeruginosa
• - Tygacilan/N (%) Vancomycin/Aztreonambn/N (%)
• -CE 365/422 (86.5) 364/411 (88.6)
• -c-mITT 429/538 (79.7) 425/519 (81.9)
• + Tygacila n/N (%) Vancomycin/Aztreonamb n/N (%)
• +CE 365/422 (86.5) 364/411 (88.6)
• +c-mITT 429/538 (79.7) 425/519 (81.9)
• - Tygacilan/N (%) Imipenem/Cilastatinbn/N (%)
• -ME 441/512 (86.1) 442/513 (86.2)
• -m-mITT 506/631 (80.2) 514/631 (81.5)
• + Tygacila n/N (%) Imipenem/Cilastatinb n/N (%)
• +ME 441/512 (86.1) 442/513 (86.2)
• +m-mITT 506/631 (80.2) 514/631 (81.5)